Preclinical mouse data point to a delivery strategy designed to neutralize adenosine-driven immunosuppression inside tumors. Researchers engineered tumor-homing nanoparticles that co-deliver CRISPR gene editors with doxorubicin to permanently disable CD73. The report says this reversed adenosine-mediated immunosuppression and shrank tumors in mouse models. If validated beyond mice, the approach suggests a combined modality in which gene editing reshapes the tumor immune landscape while chemotherapy provides cytotoxic pressure. The translational read-through is that nanoparticle targeting and durable CD73 knockout may be central to achieving stronger immune responses than chemotherapy alone.
Get the Daily Brief